Gan & Lee Pharmaceuticals.'s (SHSE:603087) Largest Shareholder, Top Key Executive Gan Zhongru Sees Holdings Value Fall by 3.2% Following Recent Drop
Gan & Lee Pharmaceuticals.'s (SHSE:603087) Largest Shareholder, Top Key Executive Gan Zhongru Sees Holdings Value Fall by 3.2% Following Recent Drop
Key Insights
关键见解
- Insiders appear to have a vested interest in Gan & Lee Pharmaceuticals' growth, as seen by their sizeable ownership
- 51% of the business is held by the top 3 shareholders
- Ownership research, combined with past performance data can help provide a good understanding of opportunities in a stock
- 内部人士似乎对Gan & Lee Pharmicals的增长拥有既得利益，他们的庞大所有权就证明了这一点
- 51% 的业务由前三名股东持有
- 所有权研究与过去的表现数据相结合，可以帮助人们更好地了解股票的机会
If you want to know who really controls Gan & Lee Pharmaceuticals. (SHSE:603087), then you'll have to look at the makeup of its share registry. With 33% stake, individual insiders possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk).
如果你想知道谁真正控制着甘李制药。(SHSE: 603087)，那么你必须看看它的股票注册表的构成。个人内部人士拥有33％的股份，拥有公司的最大股份。换句话说，该集团面临最大的上行潜力（或下行风险）。
And last week, insiders endured the biggest losses as the stock fell by 3.2%.
上周，该股下跌了3.2％，内部人士遭受了最大的损失。
Let's delve deeper into each type of owner of Gan & Lee Pharmaceuticals, beginning with the chart below.
让我们从下图开始，深入研究Gan & Lee Pharmicals的每种类型的所有者。
See our latest analysis for Gan & Lee Pharmaceuticals
查看我们对 Gan & Lee 制药的最新分析
What Does The Institutional Ownership Tell Us About Gan & Lee Pharmaceuticals?
关于甘李制药，机构所有权告诉我们什么？
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
许多机构根据近似于当地市场的指数来衡量自己的表现。因此，他们通常会更多地关注主要指数中包含的公司。
We can see that Gan & Lee Pharmaceuticals does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Gan & Lee Pharmaceuticals, (below). Of course, keep in mind that there are other factors to consider, too.
我们可以看出，Gan & Lee Pharmicals确实有机构投资者；他们持有该公司的很大一部分股票。这可以表明该公司在投资界具有一定程度的信誉。但是，最好谨慎行事，不要依赖机构投资者提供的假定验证。他们也是，有时候也会犯错。如果两个大型机构投资者试图同时卖出一只股票，股价大幅下跌的情况并不少见。因此，值得一看Gan & Lee Pharmicals过去的收益轨迹（下图）。当然，请记住，还有其他因素需要考虑。
Gan & Lee Pharmaceuticals is not owned by hedge funds. Because actions speak louder than words, we consider it a good sign when insiders own a significant stake in a company. In Gan & Lee Pharmaceuticals' case, its Top Key Executive, Gan Zhongru, is the largest shareholder, holding 32% of shares outstanding. Minghua Innovation Technology Investment (Hong Kong) Co., Ltd. is the second largest shareholder owning 10.0% of common stock, and Beijing Xute Hongda Technology Co., Ltd. holds about 8.4% of the company stock.
Gan & Lee Pharmicals不归对冲基金所有。因为行动胜于雄辩，因此当内部人士拥有一家公司的大量股份时，我们认为这是一个好兆头。就甘李制药而言，其首席执行官甘忠如是最大股东，持有32％的已发行股份。明华创新科技投资（香港）有限公司是第二大股东，拥有10.0％的普通股，北京旭特宏达科技有限公司持有公司约8.4％的股份。
After doing some more digging, we found that the top 3 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions.
在进一步挖掘之后，我们发现前三名股东共同控制了公司一半以上的股份，这意味着他们拥有影响公司决策的巨大权力。
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. We're not picking up on any analyst coverage of the stock at the moment, so the company is unlikely to be widely held.
虽然研究公司的机构所有权可以为您的研究增加价值，但研究分析师的建议以更深入地了解股票的预期表现也是一种好做法。我们目前没有收到分析师对该股的任何报道，因此该公司不太可能被广泛持有。
Insider Ownership Of Gan & Lee Pharmaceuticals
甘李制药的内部所有权
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
不同国家对内部人士的定义可能略有不同，但董事会成员始终算在内。公司管理层经营业务，但首席执行官将对董事会负责，即使他或她是董事会成员。
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
大多数人认为内部所有权是积极的，因为这可能表明董事会与其他股东关系良好。但是，在某些情况下，过多的权力集中在该群体中。
Our most recent data indicates that insiders own a reasonable proportion of Gan & Lee Pharmaceuticals.. It has a market capitalization of just CN¥20b, and insiders have CN¥6.4b worth of shares in their own names. That's quite significant. Most would be pleased to see the board is investing alongside them. You may wish to access this free chart showing recent trading by insiders.
我们的最新数据表明，内部人士拥有甘李制药合理比例的股份。它的市值仅为200亿元人民币，内部人士以自己的名义持有价值64亿元的股票。这非常重要。大多数人会很高兴看到董事会与他们一起投资。您可能希望访问这张免费图表，该图表显示了内部人士最近的交易。
General Public Ownership
一般公有制
The general public-- including retail investors -- own 29% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
包括散户投资者在内的公众拥有该公司29％的股份，因此不容忽视。虽然这个团体不一定能做主，但它肯定会对公司的运营方式产生真正的影响。
Private Company Ownership
私人公司所有权
Our data indicates that Private Companies hold 29%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
我们的数据表明，私人公司持有该公司29％的股份。私人公司可能是关联方。有时，内部人士通过持有私营公司的股权而对上市公司感兴趣，而不是以个人身份获得权益。虽然很难得出任何广泛的中风结论，但值得注意的是，这是一个有待进一步研究的领域。
Next Steps:
后续步骤：
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 4 warning signs for Gan & Lee Pharmaceuticals you should be aware of, and 2 of them make us uncomfortable.
我觉得看看究竟是谁拥有一家公司非常有趣。但是，要真正获得见解，我们也需要考虑其他信息。一个很好的例子：我们发现了 甘李制药的 4 个警告标志 你应该知道，其中有两个让我们感到不舒服。
If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, backed by strong financial data.
如果你想看看另一家公司 —— 一家财务状况可能优越的公司 —— 那千万不要错过这个 免费的 有趣的公司名单，以强劲的财务数据为后盾。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意：本文中的数字是使用过去十二个月的数据计算得出的，这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗？担心内容吗？ 取得联系 直接和我们在一起。 或者，给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是笼统的。 我们仅使用公正的方法根据历史数据和分析师的预测提供评论，我们的文章无意作为财务建议。 它不构成买入或卖出任何股票的建议，也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意，我们的分析可能不考虑最新的价格敏感公司公告或定性材料。简而言之，华尔街在上述任何股票中都没有头寸。
译文内容由第三方软件翻译。